Table 2 Risk factors for overall survival in stage IB NSCLC
From: Efficacy of platinum-based adjuvant chemotherapy in T2aN0 stage IB non-small cell lung cancer
Univariate analysis | Multivariate analysis (Cox hazard model) | |||
|---|---|---|---|---|
HR (95% CI) | p value | HR (95% CI) | p value | |
Age | 1.053 (1.015-1.094) | 0.006 | 1.031 (0.995-1.069) | 0.092 |
Sex (female vs. male) | 0.571 (0.254-1.284) | 0.175 | 0.689 (0.300-1.584) | 0.381 |
ECOG 1 (vs. 0) | 2.343 (1.128-4.864) | 0.022 | 1.717 (0.804-3.668) | 0.163 |
2 (vs. 0) | 0 | 0.976 | 0 | 0.977 |
Pneumonectomy | 1.389 (0.421-4.585) | 0.590 | … | … |
Tumor size | 0.980 (0.947-1.015) | 0.264 | … | … |
Numbers of dissected lymph nodes | 0.987 (0.956-1.018) | 0.408 | … | … |
Adenocarcinoma (vs. non-adenocarcinoma) | 0.898 (0.437-1.845) | 0.769 | … | … |
Differentiation (moderate to poor vs. well) | 1.317 (0.638-2.944) | 0.419 | … | … |
Lymphovascular invasion | 0.494 (0.115-2.110) | 0.341 | … | … |
Pleural invasion (pl2 and pl1 vs. pl0) | 1.228 (0.524-2.875) | 0.637 | … | … |
Platinum based chemotherapy (vs. no adjuvant therapy) | 0.360 (0.159-0.813) | 0.014 | 0.428 (0.184-0.998) | 0.049 |